2019

ORPHELIA Pharma announces Orphan Drug Designation granted by FDA for temozolomide in the treatment of neuroblastoma

Newsletter november 2019

It has been a busy year for our Endowment Fund and Corporate Foundation!

Two new projects supported by our Foundation

The 22th of november 2019, the board of directors of the Foundation Dominique & Tom Alberici decided to support “APPEL” and “le Gai-Rire”,

ORPHELIA Pharma announces the granting of the Marketing Authorisation for Ivozall® from the European Commission

Preclinical data of novel ICI combination with anti-PD1 or anti-CTLA4 therapies

ORPHELIA Pharma and Veriton Pharma execute a license and distribution agreement for Kigabeq® in the United Kingdom

ORPHELIA announces the appointment of Dr. Caroline Lemarchand as Chief Pharmaceutical Development Officer

First-in-class immune checkpoint inhibitor to be presented at SITC

ORPHELIA announces that the CHMP has adopted a positive opinion for Ivozall®

Ivozall® is an essential medicine intended for the treatment of relapsed or refractory Acute Lymphoblastic Leukaemia in children

Baikowski® hereby confirms its acquisition of Mathym SAS, a company with which it commenced negotiations in July 2019